Allogeneic MSCs were collected and suspended in 100 ml of 0.9% NaCl at a density of 1.0 × 106 cells/kg body weight. The enrolled patients received nine total doses of MSC infusion, including the first time, which involved the infusion of 10% of the MSCs through the portal vein after graft reperfusion and 90% of the MSCs being transfused through the peripheral vein during LT; the subsequent 8 infusions (1 week, 2 weeks, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 20 weeks, and 24 weeks after operation) were administered intravenously via the forearm. During the infusion, the MSC suspension was transfused within 30 min and swung gently every 3 min to avoid cell deposition. All patients were observed for 2 h after the transfusion to screen for any adverse events.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.